The stock of Ironwood Pharmaceuticals Inc (IRWD) has seen a 5.46% increase in the past week, with a -1.77% drop in the past month, and a -33.93% decrease in the past quarter. The volatility ratio for the week is 5.12%, and the volatility levels for the past 30 days are at 5.74% for IRWD. The simple moving average for the last 20 days is 5.97% for IRWD stock, with a simple moving average of -43.54% for the last 200 days.
Is It Worth Investing in Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Right Now?
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has a price-to-earnings ratio that is above its average at 102.78x. The stock has a 36-month beta value of 0.47. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 3 as “overweight,” 5 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IRWD is 155.59M, and at present, short sellers hold a 7.58% of that float. On October 18, 2024, the average trading volume of IRWD was 1.92M shares.
IRWD) stock’s latest price update
The stock price of Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has plunged by -1.33 when compared to previous closing price of 4.50, but the company has seen a 5.46% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-09 that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Matt Roache – Director of Investor Relations Tom McCourt – Chief Executive Officer Mike Shetzline – Chief Medical Officer Sravan Emany – Chief Operating Officer & Chief Financial Officer Andrew Davis – Chief Business Officer Conference Call Participants David Amsellem – Piper Sandler Amy Li – Jefferies Mohit Bansal – Wells Fargo Jason Butler – Citizens JMP Tim Chiang – Capital One Operator Thank you for standing by. My name, Celine, and I will be your conference operator today.
Analysts’ Opinion of IRWD
Many brokerage firms have already submitted their reports for IRWD stocks, with Leerink Partners repeating the rating for IRWD by listing it as a “Market Perform.” The predicted price for IRWD in the upcoming period, according to Leerink Partners is $5 based on the research report published on September 09, 2024 of the current year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see IRWD reach a price target of $4, previously predicting the price at $12. The rating they have provided for IRWD stocks is “Equal Weight” according to the report published on August 08th, 2024.
Craig Hallum gave a rating of “Buy” to IRWD, setting the target price at $21 in the report published on January 17th of the current year.
IRWD Trading at 0.19% from the 50-Day Moving Average
After a stumble in the market that brought IRWD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.72% of loss for the given period.
Volatility was left at 5.74%, however, over the last 30 days, the volatility rate increased by 5.12%, as shares sank -1.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.12% lower at present.
During the last 5 trading sessions, IRWD rose by +5.46%, which changed the moving average for the period of 200-days by -64.22% in comparison to the 20-day moving average, which settled at $4.19. In addition, Ironwood Pharmaceuticals Inc saw -61.19% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IRWD starting from John Minardo, who sale 9,910 shares at the price of $4.27 back on Aug 12 ’24. After this action, John Minardo now owns 284,661 shares of Ironwood Pharmaceuticals Inc, valued at $42,316 using the latest closing price.
Silver Ronald, the Principal Accounting Officer of Ironwood Pharmaceuticals Inc, sale 3,107 shares at $4.27 during a trade that took place back on Aug 12 ’24, which means that Silver Ronald is holding 158,370 shares at $13,267 based on the most recent closing price.
Stock Fundamentals for IRWD
Current profitability levels for the company are sitting at:
- 0.31 for the present operating margin
- 0.99 for the gross margin
The net margin for Ironwood Pharmaceuticals Inc stands at 0.02. The total capital return value is set at 0.35. Equity return is now at value -559.14, with 1.84 for asset returns.
Based on Ironwood Pharmaceuticals Inc (IRWD), the company’s capital structure generated 2.05 points at debt to capital in total, while cash flow to debt ratio is standing at 0.23. The debt to equity ratio resting at -1.95. The interest coverage ratio of the stock is 3.78.
Currently, EBITDA for the company is 210.61 million with net debt to EBITDA at 4.09. When we switch over and look at the enterprise to sales, we see a ratio of 3.11. The receivables turnover for the company is 6.89for trailing twelve months and the total asset turnover is 1.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.92.
Conclusion
To sum up, Ironwood Pharmaceuticals Inc (IRWD) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
